Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -72.5 Million SEK | -5.89% |
| 2022 | -68.46 Million SEK | 73.06% |
| 2021 | -254.14 Million SEK | 41.62% |
| 2020 | -435.33 Million SEK | -92.94% |
| 2019 | -225.62 Million SEK | 41.57% |
| 2018 | -386.13 Million SEK | -100.67% |
| 2017 | -192.42 Million SEK | 25.73% |
| 2016 | -259.09 Million SEK | -241.96% |
| 2015 | -75.76 Million SEK | -138.23% |
| 2014 | -31.8 Million SEK | -781.8% |
| 2013 | -3.6 Million SEK | -420.54% |
| 2012 | -692.89 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -42.38 Million SEK | 41.54% |
| 2024 Q2 | -28.04 Million SEK | 33.82% |
| 2023 Q4 | -72.5 Million SEK | 9.81% |
| 2023 FY | -72.5 Million SEK | -5.89% |
| 2023 Q1 | -32.3 Million SEK | 52.82% |
| 2023 Q2 | -115.92 Million SEK | -258.89% |
| 2023 Q3 | -80.38 Million SEK | 30.65% |
| 2022 FY | -68.46 Million SEK | 73.06% |
| 2022 Q4 | -68.46 Million SEK | 42.45% |
| 2022 Q3 | -118.97 Million SEK | 24.25% |
| 2022 Q2 | -157.06 Million SEK | 21.09% |
| 2022 Q1 | -199.04 Million SEK | 21.68% |
| 2021 Q2 | -345.51 Million SEK | 10.91% |
| 2021 Q3 | -304.63 Million SEK | 11.83% |
| 2021 Q4 | -254.14 Million SEK | 16.57% |
| 2021 FY | -254.14 Million SEK | 41.62% |
| 2021 Q1 | -387.84 Million SEK | 10.91% |
| 2020 Q4 | -435.33 Million SEK | 8.59% |
| 2020 FY | -435.33 Million SEK | -92.94% |
| 2020 Q3 | -476.21 Million SEK | 8.53% |
| 2020 Q2 | -520.61 Million SEK | -179.8% |
| 2020 Q1 | -186.06 Million SEK | 17.53% |
| 2019 Q2 | -294.12 Million SEK | 9.68% |
| 2019 Q1 | -325.63 Million SEK | 15.67% |
| 2019 FY | -225.62 Million SEK | 41.57% |
| 2019 Q4 | -225.62 Million SEK | 12.95% |
| 2019 Q3 | -259.2 Million SEK | 11.87% |
| 2018 Q4 | -386.13 Million SEK | 7.09% |
| 2018 Q2 | -447.21 Million SEK | -166.53% |
| 2018 Q3 | -415.6 Million SEK | 7.07% |
| 2018 FY | -386.13 Million SEK | -100.67% |
| 2018 Q1 | -167.79 Million SEK | 12.8% |
| 2017 Q1 | -246.36 Million SEK | 4.91% |
| 2017 Q2 | -228.32 Million SEK | 7.32% |
| 2017 Q3 | -215.3 Million SEK | 5.71% |
| 2017 Q4 | -192.42 Million SEK | 10.62% |
| 2017 FY | -192.42 Million SEK | 25.73% |
| 2016 Q2 | -59.72 Million SEK | -178.83% |
| 2016 Q1 | 75.76 Million SEK | 200.0% |
| 2016 FY | -259.09 Million SEK | -241.96% |
| 2016 Q4 | -259.09 Million SEK | 0.0% |
| 2015 Q3 | -75.76 Million SEK | -232.88% |
| 2015 Q1 | -22.76 Million SEK | 28.43% |
| 2015 Q4 | -75.76 Million SEK | 0.0% |
| 2015 FY | -75.76 Million SEK | -138.23% |
| 2015 Q2 | -22.76 Million SEK | 0.0% |
| 2014 Q1 | 3.6 Million SEK | 0.0% |
| 2014 Q4 | -31.8 Million SEK | 0.0% |
| 2014 FY | -31.8 Million SEK | -781.8% |
| 2014 Q3 | -31.8 Million SEK | 0.0% |
| 2013 FY | -3.6 Million SEK | -420.54% |
| 2012 FY | -692.89 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AroCell AB (publ) | -50.72 Million SEK | -42.937% |
| Devyser Diagnostics AB (publ) | -188.09 Million SEK | 61.456% |
| Prostatype Genomics AB (publ) | -2.61 Million SEK | -2672.543% |
| SenzaGen AB | -15.95 Million SEK | -354.529% |
| Spermosens AB | 5.02 Million SEK | 1542.826% |